The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication (STRONG)
2026年6月21日 更新者：Jiyeon Yoon、University of Pittsburgh
The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication: A Pilot Study
The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift.
•The duration of this study is 3 months. This includes:
- Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle.
- Two health assessments at baseline and at 3 months. These assessments include body composition, resting blood pressure, cardiovascular function, and muscular strength. Both the resistance exercise group and the control group will complete assessments at baseline and again at 3 months. After the 3-month period, individuals in the control group may choose to participate in the exercise training and complete the optional 6-month assessments.
- Personalized resistance exercise sessions for 60 minutes per session, twice per week, for 3 months.
調査の概要
詳細な説明
• After the baseline assessment, if participants meet all eligibility criteria such as BMI, blood pressure, physical activity levels, and medication conditions, investigators will randomly assign participants to control group or resistance exercise group:
- Control group: No resistance training during the first 3 months. After the 3-month period, participants may choose to participate in the optional exercise program, which includes 60 min/session, all for 2 sessions/week for 3 months. Participants may follow their provider's guidance for exercise except not to perform any strength or resistance training.
Resistance exercise group: 60 min/session, all for 2 sessions/week for 3 months.
- Resistance exercise group (60 min/session): Each session will be 60 minutes of resistance, performing 3 sets of 8-20 repetitions (50-80% 1RM) of 11 exercises (chest press, lat pulldown, abdominal crunch, leg press, shoulder press, weighted row, leg extension, leg curl, chest fly, biceps curl, and triceps extension) using weight training machines.
Investigator will also ask participants to maintain their usual (pre-study) lifestyle physical activity outside of exercise sessions and to monitor participants' daily activity throughout the study period using pedometers and a lifestyle activity log.
研究の種類
介入
入学 (推定)
40
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Jiyeon Yoon, M.S.
- 電話番号：512-817-4601
- メール：jiy239@pitt.edu
研究場所
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15219
- 募集
- Physical Activity Research Center, University of Pittsburgh
-
コンタクト：
- Jiyeon Yoon, M.S.
- 電話番号：515-817-4601
- メール：jiy239@pitt.edu
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Initiating GLP-1 RAs prescribed by physician or advanced practice practitioner and willing to withhold the start of the drug until baseline assessment completed
- Non-Smoker
- ≥18 years old
- Obese: Body Mass Index 30-45 kg/m² or BMI ≥27 + ≥1 weight related comorbidity; either hypertension or sleep apnea confirmed by participant self-report
- Inactive: not meeting the current US exercise guidelines over the past 6 months
- Capable of performing the required exercise training
Exclusion Criteria:
- A serious heart condition, such as unstable heart disease or heart failure, irregular heartbeats that are not well controlled, severe narrowing of the heart valves, or any recent inflammation of the heart or its lining
- Cancer requiring treatment in the past 5 years
- Hypothyroidism/hyperthyroidism
- Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome type 2 (MEN2)
- Gastroparesis
- Chronic/idiopathic acute pancreatitis
- Hepatic disease or cirrhosis
- Struggle with alcohol or other substance abuse (heavy drinking (≥4 drinks/day or ≥8 drinks/week for women; ≥5 drinks/day or ≥15 drinks/week for men), or who score ≥3 on the Drug Abuse Screening Test (DAST-10))
- Diabetes (Type 1 or 2)
- Major risk factors for coronary heart disease such as uncontrolled high blood pressure (≥160 mm Hg systolic or ≥100 mm Hg diastolic)
- Problems with your muscles or bones that limit your ability to exercise
- Any other medical condition that is life-threatening, can interfere with or be aggravated by the exercise training
- Plans to be away ≥2 weeks in the next 3 months
- Participation in any other concurrent interventional clinical trial
- History of eating disorders or weight-loss surgery, unstable weight (±5% change in past 6 months), or use of obesity medication (e.g., such as Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro) in the last 3 months
- Inability to give informed consent
- History of major depression or other severe psychiatric disorders (e.g., who answer "yes" to question 9 on PHQ-9 in the Psych_QoL_Sleep questionnaires.)
- Pregnant or plan to become pregnant during study
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Resistance Exercise (RE)
Participants will perform 60 min of resistance exercise 2 sessions per week for 12 weeks while continuing GLP-1 RAs therapy as prescribed by regular treating provider
|
60 min/session, all for 2 sessions/week for 12 weeks
Participants will take GLP-1 RAs for 12 weeks
|
|
アクティブコンパレータ：Standard Care
Participants will take GLP-1 RAs for 12 weeks as prescribed by regular treating provider
|
Participants will take GLP-1 RAs for 12 weeks
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Body Composition
時間枠：From Baseline to Week 12
|
Dual-energy X-ray absorptiometry (DEXA) will be used to assess fat mass and lean mass.
Body fat will be expressed as a percentage of total body composition, and lean mass will be expressed as a percentage of total body composition.
Change in each variable will be calculated as the Week 12 value minus the baseline value.
Positive values indicate an increase in body fat or lean mass, and negative values indicate a decrease.
|
From Baseline to Week 12
|
|
Change in Quality of Life
時間枠：From Baseline to Week 12
|
Quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36).
Scores range from 0 to 100, with higher scores indicating better quality of life.
Change will be calculated as Week 12 minus baseline.
|
From Baseline to Week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Muscle Strength
時間枠：From Baseline to Week 12
|
Grip strength will be measured three times in each hand using a Jamar dynamometer, and one-repetition maximum (1RM) will be measured using leg press and chest press machines.
|
From Baseline to Week 12
|
|
Energy Intake
時間枠：From Baseline to Week 12
|
Energy intake will be assessed using the Automated Self-Administered 24-hour (ASA24) dietary assessment tool.
|
From Baseline to Week 12
|
|
Physical Activity and Sleep
時間枠：From Baseline to Week 12
|
Participants will be asked to wear a GENEActiv tri-axial wrist-worn accelerometer for a 7-day period to quantify physical activity and sedentary behavior.
Participants will be instructed to wear the device continuously for 24 hours per day throughout the 7-day measurement period.
|
From Baseline to Week 12
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cardiovascular Fitness
時間枠：From Baseline to Week 12
|
Cardiovascular fitness will be assessed using a submaximal treadmill test with the Balke-Ware protocol.
|
From Baseline to Week 12
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- 主任研究者：Jiyeon Yoon, M.S.、University of Pittsburgh
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年5月25日
一次修了 (推定)
2027年4月30日
研究の完了 (推定)
2027年5月31日
試験登録日
最初に提出
2026年1月11日
QC基準を満たした最初の提出物
2026年6月10日
最初の投稿 (実際)
2026年6月17日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月24日
QC基準を満たした最後の更新が送信されました
2026年6月21日
最終確認日
2026年6月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- STUDY25090068
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
Datasets will be available to outside researchers and public health professionals through the web sites of ClinicalTrials.gov
and The Physical Activity Research Center (PARC) at the University of Pittsburgh.
Outside researchers can learn what data are available and request a de-identified dataset (stripped of all personal health identifiers).
All data requests will be discussed with the research team and approval will be obtained from the institutional review board overseeing the proposal of the data analysis project.
Findings from the proposed study will also be published in peer-reviewed journals.
The investigators seek to maximize the knowledge generated from this study by sharing data to expedite the translation of research into practice, with the goal of preserving lean body mass and improving quality of life.
IPD 共有サポート情報タイプ
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。